Search

Your search keyword '"Qiu Weiyi"' showing total 19 results
Start Over Author "Qiu Weiyi" Publication Year Range Last 10 years
19 results on '"Qiu Weiyi"'

4. Data Resource Profile: Egress Behavior from Select NYC COVID-19 Exposed Health Facilities March-May 2020

Author

Laefer, Debra F., Kirchner, Thomas, Haoran, Jiang, Cheong, Darlene, Yunqi, Khan, Aseah, Qiu, Weiyi, Tai, Nikki, Truong, Tiffany, and Virk, Maimunah

Subjects
Computer Science - Computers and Society
Abstract

Vector control strategies are central to the mitigation and containment of COVID-19 and have come in the form of municipal ordinances that restrict the operational status of public and private spaces and associated services. Yet, little is known about specific population responses in terms of risk behaviors. To help understand the impact of those vector control variable strategies, a multi-week, multi-site observational study was undertaken outside of 19 New York City medical facilities during the peak of the city's initial COVID-19 wave (03/22/20-05/19/20). The aim was to capture perishable data of the touch, destination choice, and PPE usage behavior of individuals egressing hospitals and urgent care centers. A major goal was to establish an empirical basis for future research on the way people interact with three-dimensional vector environments. Anonymized data were collected via smart phones. Each data record includes the time, data, and location of an individual leaving a healthcare facility, their routing, interactions with the build environment, other individuals, and themselves. Most records also note their PPE usage, destination, intermediary stops, and transportation choices. The records were linked with 61 socio-economic factors by the facility zip code and 7 contemporaneous weather factors and the merged in a unified shapefile in an ARCGIS system. This paper describes the project team and protocols used to produce over 5,100 publicly accessible observational records and an affiliated codebook that can be used to study linkages between individual behaviors and on-the-ground conditions., Comment: 14 Pages, 4 figures

Published
2021

13. PRSS contributes to cetuximab resistance in colorectal cancer

Author

Tan, Zhaoli, primary, Gao, Lihua, additional, Wang, Yan, additional, Yin, Huihui, additional, Xi, Yongyi, additional, Wu, Xiaojie, additional, Shao, Yong, additional, Qiu, Weiyi, additional, Du, Peng, additional, Shen, Wenlong, additional, Fu, Ling, additional, Jia, Ru, additional, Zhao, Chuanhua, additional, Zhang, Yun, additional, Zhao, Zhihu, additional, Sun, Zhiwei, additional, Chen, Hongxing, additional, Hu, Xianwen, additional, Xu, Jianming, additional, and Wang, Youliang, additional

Published
2020
Full Text
View/download PDF

14. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

Author

Qiu, Weiyi, primary, Zhang, Chang, additional, Wang, Shuang, additional, Yu, Xiaoyan, additional, Wang, Qiong, additional, Zeng, Dadi, additional, Du, Peng, additional, Ma, Jinling, additional, Zheng, Yiqiong, additional, Pang, Bo, additional, Yu, Yunzhou, additional, Long, Feng, additional, Pang, Xiaobin, additional, and Sun, Zhiwei, additional

Published
2019
Full Text
View/download PDF

15. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer

Author

Shuang Wang, Sun Zhiwei, Fan Jiangfeng, Da-di Zeng, Ang Chen, Xiao-peng Yang, Qiang Sun, Peng Du, Lei Xu, Weicai Zhang, and Qiu Weiyi

Subjects
0301 basic medicine, Phage display, Time Factors, Phagocytosis, Mice, Nude, CD47 Antigen, Antibodies, 03 medical and health sciences, Antineoplastic Agents, Immunological, cell-in-cell, Blocking antibody, Medicine, Animals, Humans, CD47, anti-CD47 antibody, Mice, Inbred BALB C, biology, Dose-Response Relationship, Drug, business.industry, Macrophages, Cancer, phagocytosis, U937 Cells, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Xenograft Model Antitumor Assays, Immune checkpoint, Coculture Techniques, Leukemia, Myeloid, Acute, 030104 developmental biology, HEK293 Cells, Oncology, Cancer cell, Immunology, biology.protein, cancer therapy, Antibody, business, Cell Surface Display Techniques, Research Paper
Abstract

// Dadi Zeng 1, * , Qiang Sun 1, * , Ang Chen 1 , Jiangfeng Fan 1 , Xiaopeng Yang 1 , Lei Xu 1 , Peng Du 1 , Weiyi Qiu 1 , Weicai Zhang 1 , Shuang Wang 1 , Zhiwei Sun 1 1 Beijing Institute of Biotechnology, Fengtai District, Beijing 100071, China * These two authors contributed equally to this work Correspondence to: Zhiwei Sun, email: szwyhhh@aliyun.com Shuang Wang, email: 18910810680@163.com Weicai Zhang, email: drzhangweicai@163.com Keywords: CD47, anti-CD47 antibody, phagocytosis, cancer therapy, cell-in-cell Received: March 17, 2016 Accepted: October 17, 2016 Published: November 15, 2016 ABSTRACT CD47/SIRPα interaction serves as an immune checkpoint for macrophage-mediated phagocytosis. Mouse anti-CD47 blocking antibodies had demonstrated potent efficacy in the treatment of both leukemic and solid tumors in preclinical experimentations, and therefore had moved forward rapidly into clinical trials. However, a fully human blocking antibody, which meets clinical purpose better, has not been reported for CD47 up to date. In this study, we reported the isolation of a fully human anti-CD47 blocking antibody, ZF1, from a phage display library. ZF1 displayed high specificity and affinity for CD47 protein, which were comparable to those for humanized anti-CD47 blocking antibody B6H12. Importantly, ZF1 treatment could induce robust, or even stronger than B6H12, phagocytosis of leukemic cancer cells by macrophage in vitro , and protect BALB/c nude mice from cancer killing by engrafted leukemic cells (CCRF and U937) to a similar extent as B6H12 did. Thus, these data provide primary early pre-clinical support for the development of ZF1 as a fully human blocking antibody to treat human leukemia by targeting CD47 molecule.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results